Home > Insider Trading > Filing (0001209191-23-005234)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1334365	Yuchun Lee	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-25	4,000	$72.14	5,875	No	4	M	Direct
Common Stock	Disposition	2023-01-25	800	$312.80	5,075	No	4	S	Direct
Common Stock	Disposition	2023-01-25	2,621	$314.10	2,454	No	4	S	Direct
Common Stock	Disposition	2023-01-25	579	$314.95	1,875	No	4	S	Direct
Common Stock	Acquisiton	2023-01-26	4,000	$72.14	5,875	No	4	M	Direct
Common Stock	Disposition	2023-01-26	302	$315.42	5,573	No	4	S	Direct
Common Stock	Disposition	2023-01-26	1,140	$316.82	4,433	No	4	S	Direct
Common Stock	Disposition	2023-01-26	1,000	$317.95	3,433	No	4	S	Direct
Common Stock	Disposition	2023-01-26	478	$319.25	2,955	No	4	S	Direct
Common Stock	Disposition	2023-01-26	400	$320.25	2,555	No	4	S	Direct
Common Stock	Disposition	2023-01-26	680	$320.94	1,875	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-25	4,000	$0.00	4,000	$72.14
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-26	4,000	$0.00	4,000	$72.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,429		2024-05-31	No	4	M	Direct
1,429		2024-05-31	No	4	M	Direct

Footnotes

Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $312.80 (range $312.41 to $313.06).
Open market sales reported on this line occurred at a weighted average price of $314.10 (range $313.53 to $314.50).
Open market sales reported on this line occurred at a weighted average price of $314.95 (range $314.58 to $315.14).
Open market sales reported on this line occurred at a weighted average price of $315.42 (range $315.23 to $315.66).
Open market sales reported on this line occurred at a weighted average price of $316.82 (range $316.23 to $317.16).
Open market sales reported on this line occurred at a weighted average price of $317.95 (range $317.43 to $318.35).
Open market sales reported on this line occurred at a weighted average price of $319.25 (range $318.79 to $319.56).
Open market sales reported on this line occurred at a weighted average price of $320.25 (range $319.80 to $320.77).
Open market sales reported on this line occurred at a weighted average price of $320.94 (range $320.89 to $320.99).
Fully vested.